Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors

被引:0
|
作者
Adisak Tantiworawit
Pimlak Charoenkwan
Sasinee Hantrakool
Worawut Choeyprasert
Chate Sivasomboon
Torpong Sanguansermsri
机构
[1] Chiang Mai University,Department of Internal Medicine, Faculty of Medicine
[2] Chiang Mai University,Department of Pediatrics, Faculty of Medicine
[3] Chiang Mai University,Department of Radiology, Faculty of Medicine
来源
关键词
Ferritin; Genotype; Iron overload; Liver iron concentration; Non-transfusion-dependent thalassemia; Prevalence; Risk factor;
D O I
暂无
中图分类号
学科分类号
摘要
In the present study, we sought to determine the prevalence of iron overload in patients with non-transfusion-dependent thalassemia (NTDT) and its association with genotype and other clinical risk factors, and to evaluate the correlation between serum ferritin (SF) and liver iron concentration (LIC). Myocardial and liver iron concentration was measured by MRI using a T2* gradient multi-echo sequence in NTDT patients, aged 10–50 years. Of 91 patients, 54 (59 %) had hepatic iron overload. None had cardiac iron overload. The clinical risk factors for hepatic iron overload were age >20 years (adjusted OR 30.2, 95 % CI 4.5–203, p < 0.001), hemoglobin level <7 g/dL (adjusted OR 6.3, 95 % CI 1.01–39.5, p = 0.049), and cumulative RBC transfusion >10 units (adjusted OR 53.6, 95 % CI 3.2–884, p = 0.005). Beta-thalassemia genotype was associated with higher risk of iron overload by univariate analysis, but the association was not significant when adjusted for other clinical factors. The correlation coefficient between SF and LIC was 0.60 (p < 0.001). In conclusion, the prevalence of hepatic iron overload is high in NTDT. Older age, lower hemoglobin level, and higher cumulative RBC transfusion are significant risk factors. SF and LIC show a significant positive correlation.
引用
收藏
页码:643 / 648
页数:5
相关论文
共 50 条
  • [41] Pulmonary hypertension in non-transfusion-dependent thalassemia: Correlation with clinical parameters, liver iron concentration, and non-transferrin-bound iron
    Inthawong, Kunrada
    Charoenkwan, Pimlak
    Silvilairat, Suchaya
    Tantiworawit, Adisak
    Phrommintikul, Arintaya
    Choeyprasert, Worawut
    Natesirinilkul, Rungrote
    Siwasomboon, Chate
    Visrutaratna, Pannee
    Srichairatanakool, Somdet
    Chattipakorn, Nipon
    Sanguansermsri, Torpong
    HEMATOLOGY, 2015, 20 (10) : 610 - 617
  • [42] Magnitude of Bone Disease in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia Patients
    Shamoon, Rawand P.
    Yassin, Ahmed K.
    Omar, Negar
    Saeed, Muhammad D.
    Akram, Reving
    Othman, Naska N.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [43] Disease severity scoring system for non-transfusion-dependent thalassemia
    Wiwanitkit, Somsri
    Wiwanitkit, Viroj
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 30 : E11 - E11
  • [44] HYDROXYUREA FOR NON-TRANSFUSION-DEPENDENT β-THALASSEMIA: A META-ANALYSIS
    Algiraigri, Ali
    Wright, Nicola
    Kassam, Aliya
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 56 - 56
  • [45] Recent advances in the molecular understanding of non-transfusion-dependent thalassemia
    Galanello, Renzo
    BLOOD REVIEWS, 2012, 26 : S7 - S11
  • [46] Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
    Porter, John B.
    Cappellini, Maria Domenica
    Kattamis, Antonis
    Viprakasit, Vip
    Musallam, Khaled M.
    Zhu, Zewen
    Taher, Ali T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (02) : 288 - 299
  • [47] Deferasirox: A Review of Its Use for Chronic Iron Overload in Patients with Non-Transfusion-Dependent Thalassaemia
    Matt Shirley
    Greg L. Plosker
    Drugs, 2014, 74 : 1017 - 1027
  • [48] Deferasirox: A Review of Its Use for Chronic Iron Overload in Patients with Non-Transfusion-Dependent Thalassaemia
    Shirley, Matt
    Plosker, Greg L.
    DRUGS, 2014, 74 (09) : 1017 - 1027
  • [49] Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
    Ricchi, Paolo
    Marsella, Maria
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6475 - 6482
  • [50] Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years
    Musallam, Khaled M.
    Rivella, Stefano
    Taher, Ali T.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : E57 - E59